NCT06079164View on ClinicalTrials.gov

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Relapsed/Refractory Large B-cell Lymphoma
Interventions
DRUG

KITE-197

A single infusion of CAR-transduced autologous T cells administered intravenously

DRUG

Cyclophosphamide

Lymphodepleting chemotherapy administered intravenously

DRUG

Fludarabine

Lymphodepleting chemotherapy administered intravenously

Trial Locations (11)

2050

Royal Prince Alfred Hospital, Camperdown

3004

The Alfred Hospital, Melbourne

4101

Royal Brisbane and Women's Hospital, South Brisbane

33136

Sylvester Comprehensive Cancer Center, Miami

37232

Henry-Joyce Cancer Clinic, Nashville

60637

University of Chicago Medical Center, Chicago

78704

St. David's South Austin Medical Center, Austin

98104

Swedish Cancer Institute, Seattle

T6G 1Z2

Cross Cancer Institute, Edmonton

B3H 2Y9

QEII Health Sciences Centre, Halifax

H3T 1E2

Jewish General Hospital, Montreal

All Listed Sponsors
lead

Kite, A Gilead Company

INDUSTRY

NCT06079164 - Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter